Contribution of peripheral @entity1024 receptors to XXXX expression in the trigeminal spinal nucleus following acute masseteric inflammation.

@entity1024 @entity4 @entity5019 @entity143 @entity35 @entity3390 @entity121
In this study, we examined the contribution of @entity1024 ( @entity143 ) receptors on @entity5019 expression in the trigeminal brainstem nuclei following acute @entity121 . Mustard oil (MO; 20%, 30 microL) injected into the masseter muscle induced extensive @entity4 and Fos-like immunoreactivity (Fos-LI) in several trigeminal brainstem areas including the subnucleus caudalis of the trigeminal spinal nucleus (Vc), the ventral and dorsal regions of the Vc/subnucleus interpolaris transition zone, and the paratrigeminal nucleus. In order to assess the effect of antagonizing @entity143 receptors on MO-induced Fos-LI, @entity35 were pre-treated with two different doses of i.v. @entity3390 (0.3 mg/kg, 3 mg/kg), a non-competitive @entity143 receptor antagonist, 30 min prior to MO injection. Additional groups of @entity35 received @entity3390 (0.3 mg/kg) directly in the masseter muscle or in the biceps muscle 5 min prior to MO injection. A higher dose of i.v. @entity3390 (3 mg/kg) and @entity3390 given locally into the masseter muscle (0.3 mg/kg) produced a significant reduction in total number of MO-induced Fos-LI. Further analyses revealed that pre-treatment with @entity3390 (3 mg/kg i.v.) significantly reduced the Fos-LI all throughout the Vc. Only at the caudal Vc, there was a dose-dependent reduction of MO induced Fos-LI. Pre-treatment with masseteric @entity3390 also significantly reduced the Fos-LI in the caudal Vc, with the effect greater than that produced by the same dose of @entity3390 given intravenously. These results suggest that peripheral @entity143 receptors contribute to nociceptive processing from craniofacial muscles.
